STUDIO

Cyxone updates on study results

BioStock Studio: Cyxone comments on the Covid-19 study result

Biotech company Cyxone has announced results from their phase II trial with drug candidate Rabeximod in patients with moderate to severe Covid-19. The data...

RECOMMENDED READING

FDA

BioInvent’s CMO on the positive FDA decision

BioInvent has been granted orphan drug status by the U.S. Food and Drug Administration...
PolarCool’s breakthrough year in 2021

PolarCool’s breakthrough year in 2021

In 2021, PolarCool took large strides in its ambition to bring its brain cooling...

EVENT